HIV virion capturing liposomes for therapeutic vaccination

Area of Science:

• Immunology
• Virology
• Nanotechnology

Background:

• HIV infection remains incurable, necessitating lifelong antiretroviral therapy due to viral immune evasion and mutation.
• Current treatment strategies face challenges in achieving a complete cure for HIV.

Purpose of the Study:

• To develop and evaluate a novel therapeutic vaccine, nanotrap therapeutic vaccines (NTVs), for HIV treatment.
• To assess the potential of NTVs in capturing HIV virions and eliciting anti-HIV immune responses.

Main Methods:

• NTVs are engineered liposomes displaying a CD4 mimetic (CJF288) and incorporating a TLR 7/8 agonist (R848).
• Experiments involved assessing NTVs' ability to bind gp120, capture pseudoviral particles, and facilitate antigen-presenting cell uptake.
• Efficacy was evaluated in mouse models of transient HIV infection, focusing on CD8 T cell immunity.

Main Results:

• NTVs demonstrated effective binding to gp120 and capture of pseudoviral particles.
• Uptake of NTVs by antigen-presenting cells was facilitated.
• Robust anti-HIV CD8 T cell immunity was generated in mouse models.

Conclusions:

• NTVs represent a first-in-class HIV therapeutic vaccine with the capacity to capture circulating virions.
• The technology shows translational potential for developing patient-specific HIV immunity and novel therapeutic strategies.